Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery. Gemcitabine is an important chemotherapeutic agent for patients with PDAC; however, the efficacy of gem...

Full description

Bibliographic Details
Main Authors: Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yang Liu, Xiaoqing Ma, Jinsheng Ding, Shengyu Yang, Ran Zhao, Antao Chang, Chuntao Gao, Jing Liu, Tiansuo Zhao, Xiuchao Wang, Chongbiao Huang, Song Gao, Ying Ma, Bo Tang, Yukuan Feng, Hongwei Wang, Jihui Hao
Format: Article
Language:English
Published: China Anti-Cancer Association 2023-08-01
Series:Cancer Biology & Medicine
Subjects:
gemcitabine resistance
pancreatic ductal adenocarcinoma
phospholipase d1
nucleophosmin 1
crispra library
Online Access:https://www.cancerbiomed.org/content/20/8/599

Internet

https://www.cancerbiomed.org/content/20/8/599

Similar Items